With the rising trend of colorectal cancer turning into a cause for concern, doctors raised the need for screening to ...

Colorectal cancer, most commonly known as colon cancer, has been the third most prevalent cancer worldwide, comprising about ...

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

Here are key facts, risk factors, and life-saving screening recommendations for colorectal cancer prevention and treatment.

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.

demonstrated meaningful efficacy in heavily pretreated patients with KRAS G12C–mutant unresectable or metastatic colorectal cancer, according to phase 1/2 KRYSTAL-1 trial data presented at the 2025 ...

Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in ...

Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma (HCC), the most common type of ...